34 completed, 4 not yet recruiting, 3 active not recruiting, 3 recruiting. 24 Phase 3, 14 Phase 2, 6 Phase 1, 4 Phase 4.
Follow lebrikizumab: new trials by email Literature Review of lebrikizumab trials Research Report on lebrikizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis | Phase 4 | Not yet recruiting | Forefront Dermatology S.C | 250 | 2026-11-11 | 2026-10-02 |
| A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Almirall, S.A. | 230 | 2026-11-01 | 2026-10-14 |
| Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients Lebrikizumab - Prurigo Nodularis (PN) | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 15 | 2026-09-01 | 2026-09-03 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| A Study of Lebrikizumab in Adults With Nummular Eczema Lebrikizumab, Placebo - Nummular Eczema | Phase 3 | Recruiting | Almirall, S.A. | 270 | 2026-04-24 | 2026-08-17 |
| A Study of LAD106 in Healthy Adult Participants LAD106, Lebrikizumab, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Almirall, S.A. | 93 | 2026-02-17 | 2026-05-15 |
| Lebrikizumab in Moderate-to-severe Atopic Dermatitis lebrikizumab - Atopic Dermatitis | Phase 4 | Active not recruiting | Johann E Gudjonsson MD PhD | 48 | 2025-07-02 | 2026-09-15 |
| A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden Lebrikizumab - Atopic Dermatitis | Phase 4 | Completed | Eli Lilly and Company | 233 | 2025-06-16 | 2026-10-15 |
| A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis Lebrikizumab, Placebo - Atopic Hand and Foot Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 221 | 2025-04-21 | 2026-08-20 |
| A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Dermatitis, Atopic, Eczema | Phase 3 | Active not recruiting | Almirall, S.A. | 520 | 2024-07-03 | 2026-04-21 |
| A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis Placebo, Lebrikizumab, Topical Corticosteroid - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 301 | 2024-04-24 | 2026-10-16 |
| A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants Lebrikizumab, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 24 | 2024-03-28 | 2025-09-12 |
| Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab - Atopic Dermatitis, Eczema | Phase 3 | Completed | Almirall, S.A. | 260 | 2023-11-20 | 2026-07-17 |
| Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis Lebrikizumab - Atopic Dermatitis | Phase 3 | Completed | Almirall, S.A. | 174 | 2023-05-23 | 2026-05-14 |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis, Eczema | Phase 3 | Enrolling by invitation | Eli Lilly and Company | 333 | 2023-03-09 | 2026-07-30 |
| A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color Lebrikizumab - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 90 | 2023-01-12 | 2026-03-09 |
| A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab Lebrikizumab - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 86 | 2022-12-19 | 2026-02-25 |
| A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo, Topical Corticosteroid (TCS) - Atopic Dermatitis, Eczema | Phase 3 | Active not recruiting | Eli Lilly and Company | 377 | 2022-10-18 | 2026-07-30 |
| A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine Lebrikizumab, Lebrikizumab-matching Placebo - Dermatitis, Atopic, Eczema | Phase 3 | Completed | Almirall, S.A. | 331 | 2021-12-23 | 2025-05-20 |
| A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants Lebrikizumab - Healthy | Phase 1 | Completed | Eli Lilly and Company | 242 | 2021-06-02 | 2024-11-22 |
Showing 20 of 48. Sign in to see all of them.
Dermatitis, Atopic (25) · Eczema (15) · Asthma (12) · Dermatitis (11) · Skin Diseases (11) · Psoriasis (2) · Facies (1) · Hodgkin Disease (1) · Idiopathic Pulmonary Fibrosis (1) · Prurigo (1) · Pruritus (1) · Pulmonary Disease, Chronic Obstructive (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Genetic (1) · Stereotyping (1)
Eli Lilly and Company (17) · Hoffmann-La Roche (11) · Almirall, S.A. (7) · Genentech, Inc. (7) · Forefront Dermatology S.C (1) · Johann E Gudjonsson MD PhD (1) · Prof. Dr. Stephan Weidinger (1) · Tanox (1) · University of California, San Francisco (1) · University of Maryland, Baltimore (1)
United States (33) · Canada (19) · Poland (16) · Germany (15) · Australia (13) · Spain (12) · France (11) · Mexico (11) · United Kingdom (10) · Argentina (8) · Czechia (8) · Japan (7) · South Korea (7) · Taiwan (7) · Belgium (5)
Michelle Freemer, M.D. (2) · Aleksandra Stjepanovic (1) · Anas Younes, MD (1) · Craig Moskowitz, MD (1) · Diego Ruiz Dasilva, MD (1) · Edward Conner, M.D. (1) · Johann E. Gudjonsson, MD, PhD (1) · Kristin L Khan, MD (1) · Raymond Cho, MD, PhD (1) · Stephan Weidinger, MD (1)
PMID 33217063, PMID 41206702, PMID 26001563, PMID 27616196, PMID 31803473, PMID 36920778, PMID 36994947, PMID 38679419, PMID 38700646, PMID 38922484, PMID 39002092, PMID 39123054, PMID 39249591, PMID 40663228, PMID 41435984, PMID 21812663, PMID 24131304, PMID 29413502, PMID 32101256, PMID 32909660, PMID 35688625, PMID 35846226, PMID 36630140, PMID 37318750, PMID 38363461, PMID 39009804, PMID 39039395, PMID 39442013, PMID 40549127, PMID 40665146, PMID 41553700, PMID 42315763
2019 (4), 2025 (3), 2014 (2), 2023 (2), 2015 (1)